Logo image of IBRX

IMMUNITYBIO INC (IBRX) Stock Fundamental Analysis

NASDAQ:IBRX - Nasdaq - US45256X1037 - Common Stock

3.135  -0.09 (-2.64%)

Fundamental Rating

2

Overall IBRX gets a fundamental rating of 2 out of 10. We evaluated IBRX against 572 industry peers in the Biotechnology industry. IBRX has a bad profitability rating. Also its financial health evaluation is rather negative. IBRX is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year IBRX has reported negative net income.
In the past year IBRX has reported a negative cash flow from operations.
IBRX had negative earnings in each of the past 5 years.
In the past 5 years IBRX always reported negative operating cash flow.
IBRX Yearly Net Income VS EBIT VS OCF VS FCFIBRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100M -200M -300M -400M -500M

1.2 Ratios

IBRX's Return On Assets of -161.23% is on the low side compared to the rest of the industry. IBRX is outperformed by 86.37% of its industry peers.
Industry RankSector Rank
ROA -161.23%
ROE N/A
ROIC N/A
ROA(3y)-101.5%
ROA(5y)-102.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IBRX Yearly ROA, ROE, ROICIBRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100 -100

1.3 Margins

IBRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IBRX Yearly Profit, Operating, Gross MarginsIBRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100K -200K -300K

More info and screens

2

2. Health

2.1 Basic Checks

IBRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IBRX has been increased compared to 1 year ago.
Compared to 5 years ago, IBRX has more shares outstanding
The debt/assets ratio for IBRX has been reduced compared to a year ago.
IBRX Yearly Shares OutstandingIBRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M
IBRX Yearly Total Debt VS Total AssetsIBRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

2.2 Solvency

IBRX has an Altman-Z score of -14.36. This is a bad value and indicates that IBRX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of IBRX (-14.36) is worse than 81.95% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -14.36
ROIC/WACCN/A
WACC11.62%
IBRX Yearly LT Debt VS Equity VS FCFIBRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500M -500M

2.3 Liquidity

IBRX has a Current Ratio of 2.68. This indicates that IBRX is financially healthy and has no problem in meeting its short term obligations.
IBRX's Current ratio of 2.68 is on the low side compared to the rest of the industry. IBRX is outperformed by 69.73% of its industry peers.
IBRX has a Quick Ratio of 2.64. This indicates that IBRX is financially healthy and has no problem in meeting its short term obligations.
IBRX has a worse Quick ratio (2.64) than 68.85% of its industry peers.
Industry RankSector Rank
Current Ratio 2.68
Quick Ratio 2.64
IBRX Yearly Current Assets VS Current LiabilitesIBRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 17.14% over the past year.
The Revenue has grown by 1228.26% in the past year. This is a very strong growth!
The Revenue has been growing by 65.56% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)17.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.84%
Revenue 1Y (TTM)1228.26%
Revenue growth 3Y0.65%
Revenue growth 5Y65.56%
Sales Q2Q%7346.34%

3.2 Future

Based on estimates for the next years, IBRX will show a very strong growth in Earnings Per Share. The EPS will grow by 32.45% on average per year.
Based on estimates for the next years, IBRX will show a very strong growth in Revenue. The Revenue will grow by 411.09% on average per year.
EPS Next Y24.78%
EPS Next 2Y17.99%
EPS Next 3Y16.92%
EPS Next 5Y32.45%
Revenue Next Year3039.76%
Revenue Next 2Y1549.13%
Revenue Next 3Y710.51%
Revenue Next 5Y411.09%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IBRX Yearly Revenue VS EstimatesIBRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5B 10B 15B
IBRX Yearly EPS VS EstimatesIBRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 10 15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IBRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IBRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IBRX Price Earnings VS Forward Price EarningsIBRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IBRX Per share dataIBRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as IBRX's earnings are expected to grow with 16.92% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.99%
EPS Next 3Y16.92%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IBRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMMUNITYBIO INC

NASDAQ:IBRX (1/22/2025, 10:49:58 AM)

3.135

-0.09 (-2.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)N/A N/A
Inst Owners9.08%
Inst Owner Change-0.01%
Ins Owners5.62%
Ins Owner Change0.13%
Market Cap2.29B
Analysts82.22
Price Target14.54 (363.8%)
Short Float %25.89%
Short Ratio8.76
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.65%
Min EPS beat(2)-15.34%
Max EPS beat(2)34.64%
EPS beat(4)1
Avg EPS beat(4)-23.47%
Min EPS beat(4)-90.63%
Max EPS beat(4)34.64%
EPS beat(8)3
Avg EPS beat(8)-14.85%
EPS beat(12)4
Avg EPS beat(12)-13.29%
EPS beat(16)5
Avg EPS beat(16)-16.8%
Revenue beat(2)1
Avg Revenue beat(2)22.65%
Min Revenue beat(2)-59.26%
Max Revenue beat(2)104.56%
Revenue beat(4)3
Avg Revenue beat(4)136.81%
Min Revenue beat(4)-59.26%
Max Revenue beat(4)445.1%
Revenue beat(8)7
Avg Revenue beat(8)289.49%
Revenue beat(12)10
Avg Revenue beat(12)342.66%
Revenue beat(16)13
Avg Revenue beat(16)305.53%
PT rev (1m)0%
PT rev (3m)123.53%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-13.33%
EPS NY rev (1m)0%
EPS NY rev (3m)3.1%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-60.2%
Revenue NY rev (1m)0%
Revenue NY rev (3m)9.1%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 312.2
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.87
EYN/A
EPS(NY)-0.69
Fwd EYN/A
FCF(TTM)-0.59
FCFYN/A
OCF(TTM)-0.58
OCFYN/A
SpS0.01
BVpS-1.02
TBVpS-1.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -161.23%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-101.5%
ROA(5y)-102.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 70.81%
Cap/Sales 173.65%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.68
Quick Ratio 2.64
Altman-Z -14.36
F-Score4
WACC11.62%
ROIC/WACCN/A
Cap/Depr(3y)315.06%
Cap/Depr(5y)197.77%
Cap/Sales(3y)16646%
Cap/Sales(5y)10081.4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.84%
EPS Next Y24.78%
EPS Next 2Y17.99%
EPS Next 3Y16.92%
EPS Next 5Y32.45%
Revenue 1Y (TTM)1228.26%
Revenue growth 3Y0.65%
Revenue growth 5Y65.56%
Sales Q2Q%7346.34%
Revenue Next Year3039.76%
Revenue Next 2Y1549.13%
Revenue Next 3Y710.51%
Revenue Next 5Y411.09%
EBIT growth 1Y0.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-6.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-32.33%
OCF growth 3YN/A
OCF growth 5YN/A